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Coagulation abnormalities in acute promyelocytic leukemia
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E  H E M O T E R A P I A
Acute promyelocytic leukemia is frequently accompanied by coagulation abnormalities
usually described as laboratorial disseminated intravascular coagulation, which is the
main cause of morbidity and early mortality. Aberrant activation of the coagulation
cascade and hyperfibrinolysis play an important role in the pathogenesis of bleeding
diathesis, but their contribution varies from case to case. Here we review the main
laboratorial findings and the recommended clinical management of coagulopathy
associated with acute promyelocytic leukemia. Rev. Bras. Hematol. Hemoter. 2009;
31(Supl. 2):48-50.
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Itroduction
Acute promyelocytic leukemia (APL) is invariably
associated with recurrent chromosomal abnormalities
involving the   receptor of retinoic acid (RAR ). In about 98%
of the cases the companion gene involved is the
promyelocytic leukemia gene (PML), resulting in the PML-
RARα fusion gene and a chimeric protein with reduces
sensitivity to retinoic acid. Nevertheless, pharmacological
doses of all-trans retinoic (ATRA) can disrupt this resistance
and lead to differentiation of leukemic blasts.1-7 Consequently,
protocols which associate ATRA and standard chemotherapy
have become the standard in this disease and remission rates
of almost 90% have been achieved.8,9
Clinically, a major aspect of APL is the presence of
coagulation abnormalities and about sixty percent of patients
present at least minor bleeding at diagnosis.10,11 Before the
availability of ATRA, from 10 to 30 percent of patients died
early during treatment.11-13 Despite the high cure rates
reported, the coagulopathy is still the main factor responsible
for morbidity in this disease14 and the cause of early
mortality.9
Laboratorial Hemostasis in APL
Most APL patients present at diagnosis with
prolonged prothrombin time, partial thromboplastin time and
thrombin time, hypofibrinogenemia, high D-Dimers and low
platelet counts.15-18 The thrombin-antithrombin complex
(TAT) and fibrinopeptide A are elevated, which represent
intravascular thrombin formation and activation of the
coagulation cascade in vivo suggesting that a mechanism
similar to disseminated intravascular coagulation (DIC) may
be present.
Currently, there is evidence that APL blasts express
tissue factor (TF) and secrete interleukin 1, inducing
activation of the coagulation cascade.19-21 Also, an
alternative procoagulant, namely Cancer Procoagulant,
which activates Factor X directly, is present in APL cells.22
Despite this, some peculiarities are found in APL
coagulopathy: the platelet half-life is normal,23 and protein
C and antithrombin plasmatic concentrations are normal,20,24
different from classical DIC.25 Moreover, clinical bleeding is
disproportional to laboratorial data suggesting that different
mechanisms may be involved.
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be used prophylactically. Leukocytapheresis must be avoided
due to worsening in coagulation diathesis. There is no
evidence that administration of antifibrinolytic drugs has any
beneficial effect.
Conclusion
APL is a standard for disease directed therapy.
Survival is near 90% in some trials, but bleeding remains a
major concern. Coagulation diathesis has multiple causes
and can be summarized in three points: coagulation
activation, fibrinolysis and proteolysis. An aggressive
treatment once APL is suspected is the key to reduce
morbidity and mortality.
Resumo
A leucemia promielocítica aguda (LPA) é geralmente acompanhada
por anormalidades da coagulação usualmente descritas como
coagulação intravascular disseminada e que são a principal causa
de mortalidade precoce. A ativação anormal da cascata de co-
agulação e a hiperfibrinólise desempenham importante papel na
patogênese da diátese hemorrágica, mas a contribuição de cada
fator varia de caso a caso. Apresentamos aqui uma revisão dos
principais achados laboratoriais e da recomendação para o manejo
clínico da coagulopatia associada a LPA. Rev. Bras. Hematol.
Hemoter. 2009;31(Supl. 2):48-50.
Palavras-chave: Leucemia promielocítica aguda; coagulação;
fibrinólise; coagulação intravascular disseminada.
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The detection of low levels of α2-antiplasmin,24 an
antifibrinolytic agent, implies that an hyperfibrinolytic state
may be present.26 Plasminogen activation inhibitor-1 (PAI-1)
and lower levels of fibrinogen compared to DIC highlight
fibrin lysis as an important mechanism in APL.26 Moreover,
thrombin activated fibrinolysis inhibitor is quantitatively
normal, while classically in DIC, there is consumption of this
factor.27 Additionally, the promyelocytic leukemia cell line
(NB4) can increase plasmin formation by 21 times in vitro.27
Another interesting point is the over-expression of annexin
II in APL cells.28-30 Annexin II binds to tPA and plasminogen
and improves plasmin activation by almost 200 times.
A third mechanism is involved in APL coagulopathy.
The activity of some proteolytic enzymes is above normal
and some of them can lyse fibrin. Elastase levels are raised,31
and there is evidence that it breaks down fibrin. As fibrin
degradation products have inhibitory effects on the
coagulation cascade (specially fragment D-like), this
proteolysis has an anticoagulation effect.
Therefore, APL coagulopathy is peculiar. Some
laboratorial data may suggest DIC, but the bleeding signs
are more intense than a hemostasis test could preview. There
is evidence that activation of fibrinolysis and some proteases
play an important role. Hence, the coagulation abnormalities
are due to at least three pathways which can explain why
bleeding is so significant in this disease.
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Patient management
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Concomitantly, an interesting point is to avoid classical
chemotherapy regimens, which can lead to worsening of
bleeding. Despite a growing understanding of the
pathophysiology, no specific treatment has been proposed
for coagulation abnormalities. Transfusions should keep
platelet counts above 30-40 x 106/µL and there is no
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